Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
13 evidence topics · 15 sources
Summary
In a US claims analysis of 3,409 individuals with CIDP, 2,758 (81%) were treated during the first year, and steroids (73% of those treated) followed by immunoglobulin (65%) were the most commonly used treatments. Neurology specialists are the most frequent prescribers of immunoglobulin, which may be given in a hospital clinic, physician's office, infusion clinic, or at home; the Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) prefilled syringe may be administered subcutaneously by patients or caregivers after proper instruction, and the vial is to be administered by a healthcare professional only.
The company positions claseprubart as a potential first-line biologic given as a subcutaneous, infrequently dosed, self-administered injection, and CAPTIVATE enrolls standard-of-care-refractory, standard-of-care-treated, and standard-of-care-naive patients without requiring immunoglobulin withdrawal. Other complement inhibitors are in development: Sanofi announced that the phase 3 MOBILIZE trial of riliprubart, an antibody that selectively inhibits activated C1s, in CIDP refractory to standard-of-care treatment will be stopped after an independent data monitoring committee determined at an interim analysis that it is unlikely to provide sufficient efficacy, and that continuation of VITALIZE will be evaluated accordingly; argenx is advancing two phase 3 trials of empasiprubart, an antibody targeting C2, one of them a head-to-head comparison with intravenous immunoglobulin.
Current US treatment patterns
“Among patients who received treatment in 2023, a majority in both cohorts received steroids, followed by immunoglobulin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients in both cohorts were most frequently seen by neurology specialists, and these specialists were the most frequent prescribers of immunoglobulin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 3,409 patients with CIDP identified, the majority (81% [ n = 2,758]) were treated for CIDP while 19% ( n = 651) were untreated for CIDP during 1-year post-index. Steroids (73% [ n = 2017]) followed by Ig (65% [ n = 1,803]) were most commonly utilized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting for current infused and injected therapies
“Immunoglobulin may be administered at a hospital clinic, physician’s office, free-standing infusion clinic, or at home with proper monitoring” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the costs were evaluated by site of care, home infusion visits were a primary site of care in CIDP-specific costs for the patients receiving IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote